SCHEMBL4537779

SCHEMBL4537779

N#Cc1ccc(Sc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.58
MAOB P27338 4/20 0.58
KIF11 P52732 1/20 0.47
XBP1 P17861 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
HTR2C P28335 1/20 0.43
HTR6 P50406 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
MGLL Q99685 1/20 0.41
ELANE P08246 1/20 0.41
CYP2C9 P11712 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.41
MAPT P10636 2/20 0.40
KMT2A Q03164 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP3A5 P20815 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11664820 0.83 XBP1 (0.51) XBP1KDM4EHPGDHTR2CHTR6
SCHEMBL30688819 0.82 XBP1 (0.57) XBP1KDM4EHPGDHTR2CHTR6
SCHEMBL8863159 0.82 XBP1 (0.57) XBP1KDM4EHPGDHTR2CHTR6
SCHEMBL27589778 0.81 SLC6A2 (0.54) KIF11XBP1KDM4EHPGDSLC6A2
SCHEMBL10943172 0.79 XBP1 (0.40) KIF11XBP1KDM4EHPGDHTR2C
SCHEMBL693198 0.78 XBP1 (0.48) XBP1KDM4EHPGDHTR2CHTR6
SCHEMBL5019834 0.78 TSHR (0.55) MAOBKIF11XBP1KDM4EHPGD
SCHEMBL15231640 0.78 CTSS (0.45) XBP1KDM4EHPGDSLC6A2SLC6A4
SCHEMBL161195 0.77 MAOA (0.53) MAOAMAOBMGLLCTSS
SCHEMBL11092767 0.76 KIF11 (0.63) KIF11CYP3A4CYP3A5L3MBTL1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (US) 2014-04-24 US disclosed
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (US) 2014-04-24 US disclosed
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (US) 2014-04-24 US disclosed
WO-2012061926-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS CACNA1C, CACNA1S, KCNN4 MAOA 3732/4885MAOB 2188/4885KIF11 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.